JP2022554348A5 - - Google Patents

Info

Publication number
JP2022554348A5
JP2022554348A5 JP2022525983A JP2022525983A JP2022554348A5 JP 2022554348 A5 JP2022554348 A5 JP 2022554348A5 JP 2022525983 A JP2022525983 A JP 2022525983A JP 2022525983 A JP2022525983 A JP 2022525983A JP 2022554348 A5 JP2022554348 A5 JP 2022554348A5
Authority
JP
Japan
Prior art keywords
cells
ccr7
attribute
composition
3cas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022525983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/058985 external-priority patent/WO2021092097A1/en
Publication of JP2022554348A publication Critical patent/JP2022554348A/ja
Publication of JP2022554348A5 publication Critical patent/JP2022554348A5/ja
Ceased legal-status Critical Current

Links

JP2022525983A 2019-11-05 2020-11-04 治療用t細胞組成物の属性を決定する方法 Ceased JP2022554348A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962931194P 2019-11-05 2019-11-05
US62/931,194 2019-11-05
US201962945091P 2019-12-06 2019-12-06
US62/945,091 2019-12-06
PCT/US2020/058985 WO2021092097A1 (en) 2019-11-05 2020-11-04 Methods of determining attributes of therapeutic t cell compositions

Publications (2)

Publication Number Publication Date
JP2022554348A JP2022554348A (ja) 2022-12-28
JP2022554348A5 true JP2022554348A5 (cg-RX-API-DMAC7.html) 2023-11-10

Family

ID=73599008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525983A Ceased JP2022554348A (ja) 2019-11-05 2020-11-04 治療用t細胞組成物の属性を決定する方法

Country Status (6)

Country Link
US (1) US20220412954A1 (cg-RX-API-DMAC7.html)
EP (1) EP4055383A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022554348A (cg-RX-API-DMAC7.html)
KR (1) KR20220131892A (cg-RX-API-DMAC7.html)
CN (1) CN115087868A (cg-RX-API-DMAC7.html)
WO (1) WO2021092097A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114600172A (zh) 2019-08-30 2022-06-07 朱诺治疗学股份有限公司 用于将细胞分类的机器学习方法
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
EP4665843A1 (en) * 2023-02-17 2025-12-24 LUMICKS CA Holding B.V. Means and methods for determining cellular avidity of primary t cells and target cells
KR20260115674A (ko) * 2023-11-22 2026-07-24 얀센 바이오테크 인코포레이티드 Car t 완제의약품을 최적화하기 위한 제조 시스템, 방법, 및 ai 모델
CN119648571B (zh) * 2025-02-18 2025-05-20 西湖大学 用于双光子显微镜的图像序列的处理方法、装置、系统和介质

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
ATE186235T1 (de) 1996-04-24 1999-11-15 Claude Fell Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut
DK0973928T3 (da) 1997-03-11 2010-08-09 Univ Minnesota DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
WO1999025817A2 (en) 1997-11-13 1999-05-27 Regents Of The University Of Minnesota Tc1-based transposon vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
ES2224726T3 (es) 1998-12-24 2005-03-01 Biosafe S.A. Sistema de separacion sanguinea indicado en particular para la concentracion de celulas madre hematopoyeticas.
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US7362449B2 (en) 2003-05-16 2008-04-22 Universite Libre De Bruxelles Digital holographic microscope for 3D imaging and process using it
US20080171951A1 (en) 2005-03-23 2008-07-17 Claude Fell Integrated System for Collecting, Processing and Transplanting Cell Subsets, Including Adult Stem Cells, for Regenerative Medicine
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
LT2222861T (lt) 2007-12-11 2018-03-26 The University Of North Carolina At Chapel Hill Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープCity of Hope 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
KR20160103175A (ko) 2011-07-19 2016-08-31 오비지오 이미징 시스템스 엔.브이. 세포 샘플에서의 암 세포들의 검출 및/또는 분류를 위한 방법 및 시스템
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
EP2898310B1 (en) 2012-09-20 2019-05-01 Ovizio Imaging Systems NV/SA Digital holographic microscope with fluid systems
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
JP6740234B2 (ja) 2014-11-05 2020-08-12 ジュノー セラピューティクス インコーポレイテッド 形質導入および細胞プロセシングのための方法
WO2016168595A1 (en) * 2015-04-17 2016-10-20 Barrett David Maxwell Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3525803B1 (en) 2016-10-13 2022-12-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
CA3042049A1 (en) 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
JP2019536460A (ja) 2016-12-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Car−t細胞の調節方法
PL3618842T3 (pl) 2017-05-01 2024-02-19 Juno Therapeutics, Inc. Kombinacja terapii komórkowej i związku immunomodulującego
EP4516896A3 (en) 2017-08-09 2025-05-14 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
MA50079A (fr) * 2017-09-07 2020-07-15 Juno Therapeutics Inc Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
JP7357626B2 (ja) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド 操作された細胞の治療用組成物を生成するためのプロセス
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
BR112020011223A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc marcadores fenotípicos para terapia celular e mé-todos relacionados
CN111971059A (zh) 2018-01-31 2020-11-20 细胞基因公司 使用过继细胞疗法和检查点抑制剂的组合疗法
US20210047405A1 (en) * 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
WO2020089343A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
US20210393691A1 (en) 2018-11-06 2021-12-23 Juno Therapeutics, Inc. Process for producing genetically engineered t cells

Similar Documents

Publication Publication Date Title
Busch et al. Role of memory T cell subsets for adoptive immunotherapy
Crome et al. A distinct innate lymphoid cell population regulates tumor-associated T cells
Franceschetti et al. Cytokine-induced killer cells are terminallydifferentiated activated CD8 cytotoxic T-EMRA lymphocytes
Gattinoni et al. T memory stem cells in health and disease
JP6815992B2 (ja) キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
Clark et al. A novel method for the isolation of skin resident T cells from normal and diseased human skin
Kiekens et al. T-BET and EOMES accelerate and enhance functional differentiation of human natural killer cells
Freud et al. Human natural killer cell development
Cieri et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Stemberger et al. Stem cell-like plasticity of naive and distinct memory CD8+ T cell subsets
US20200095547A1 (en) Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
JP2021534245A5 (cg-RX-API-DMAC7.html)
JP2018500944A5 (cg-RX-API-DMAC7.html)
Takeshita et al. Polarization diversity of human CD4+ stem cell memory T cells
JP2018506995A5 (cg-RX-API-DMAC7.html)
JP2023539056A5 (cg-RX-API-DMAC7.html)
JP2025507581A (ja) 抗原特異的t細胞増殖のための組成物及び方法
Malakhova et al. Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration
Bhat et al. Contemplating dichotomous nature of gamma delta T cells for immunotherapy
Gattinoni et al. Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse
Wang et al. Genomic expression profiling of NK cells in health and disease
Kretschmer et al. A single-cell perspective on memory T-cell differentiation
Bartoli-Leonard et al. Single-cell T cell receptor sequencing of paired tissue and blood samples reveals clonal expansion of CD8+ effector T cells in patients with calcific aortic valve disease
Shinkawa et al. CD226 identifies effector CD8+ T cells during tuberculosis and costimulates recognition of Mycobacterium tuberculosis-infected macrophages
Sandgaard et al. The importance of taking ART appropriately in children and adolescents with HIV-1 to reach the highest capacity of immune function later in life